Focused On-demand Library for Cardiolipin synthase (CMP-forming)

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UJA2

UPID:

CRLS1_HUMAN

Alternative names:

Protein GCD10 homolog

Alternative UPACC:

Q9UJA2; D3DW09; E9PAT4; Q27RP0; Q69YQ5

Background:

Cardiolipin synthase, also known as Protein GCD10 homolog, plays a pivotal role in mitochondrial function by catalyzing the synthesis of cardiolipin (CL). CL is crucial for maintaining mitochondrial integrity and dynamics, highlighting the protein's importance in cellular energy production and stress response.

Therapeutic significance:

The protein's involvement in Combined oxidative phosphorylation deficiency 57, a mitochondrial disease with symptoms ranging from encephalopathy to cardiac defects, underscores its potential as a therapeutic target. Understanding the role of Cardiolipin synthase could open doors to potential therapeutic strategies.